Acute-phase inflammatory response in patients with pulmonary tuberculosis

Acta Facultatis Medicae Naissensis

Volumn 31, Issue 3, 2014, Pages 183-191

  Radović, Milan ^a,b   Pejčić, Tatjana ^a,b   Stanković, Ivana ^a,b   Ristić, Lidija ^a,b   Rančić, Milan ^a,b   Ćirić, Zorica ^a,b  

^a CLINICAL CENTER NIS   (Serbia)

^b UNIVERSITY OF NI   (Serbia)

Author keywords

fibrinogen; inflammation; tuberculosis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LOWER RESPIRATORY TRACT INFECTION; LUNG LESION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; SHORT COURSE THERAPY; TREATMENT OUTCOME;

EID: 84913601358     PISSN: 03516083     EISSN: 22172521     Source Type: Journal    
DOI: 10.2478/afmnai-2014-0023     Document Type: Article

References (15)

1. Breen RA, Leonard O, Perrin FM et al. How good are systemic symptoms and blood inflammatory markers at detecting individuals with tuberculosis? Int J Tuberc Lung Dis. 2008;12:44-9.
2. Peresi E, Silva SM, Calvi SA, Marcondes-Machado J. Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J Bras Pneumol. 2008, 34: 942-9. http://dx.doi.org/10.1590/S1806-37132008001100009
3. Turken O, Kunter E, Sezer M et al. Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis. 2002;6:927-932.
4. Plit ML, Anderson R, Rensburg CEJ, et al. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J 1998;12:351-356. http://dx.doi.org/10.1183/09031936.98.12020351
5. Caner SS, Köksal D, Ozkara S et al. The relation of serum interleukin-2 and C-reactive protein levels with clinical and radiological findings in patients with pulmonary tuberculosis. Tuberk Toraks. 2007,55:238-45.
6. Ellkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology 2006; Thorax, 61: 259-266.
7. Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb). 2008,88 Suppl 1:S75-83. http://dx.doi.org/10.1016/S1472-9792(08)70038-6
8. Blasi F, Cosentini R, Migliori GB, Boersma W. Steps foward in LRTI and tuberculosis: update from the ERS Respiratory Infections Assemblly. Eur Respir J 2010; 33:1448-1454. http://dx.doi.org/10.1183/09031936.00166908
9. Ministarstvo Zdravlja Republike Srbije. Stručno-metodološko uputstvo za sprečavanje i suzbijanje tuberkuloze u Republici Srbiji. Ministarstvo Zdravlja Republike Srbije, Beograd, Srbija, 2009:11-20.
10. Heatherton TF, Kozlowski LT, Frecker RC et al. The Fagerström test for nicotine dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-1127. http://dx.doi.org/10.1111/j.1360-0443.1991.tb01879.x
11. Snider GL, Doctor L, Demas TA, Shaw AR. Obstructive airway disease in patients with treated tuberculosis. Am Rev Respir Dis 1971;103:625-640.
12. IFCC/EMD Committee on Clinical Laboratory Medicine. IFCC Statement on the use of ISO 15189 in the accreditation of medical laboratories, 2007 (available on-: http://www.ifcc.bigone.bz/PDF/ISO15189-C-CLM.pdf).
13. Kaminskaia GO, Abdullaev RI, Komissarova OG. Estimation of serum C-reactive protein values in patients with pulmonary tuberculosis. Probl Tuberk Bolezn Legk. 2008; 50-4.
14. Tönnesen P, Carrozzi L, Fagerström KO et al. Smoking cessation in patients with respiratory diseases:a high priority, integral component of therapy. Eur Respir J 2007; 29:390-417. http://dx.doi.org/10.1183/09031936.00060806
15. Gemez Y, Tirouvanziam R, Chanez P. Neutrophyls in chronic inflammatory airway diseases: can we target them and how? Eur Respir J 2010, 35: 467-469. http://dx.doi.org/10.1183/09031936.00186109